Cobenfy, a brand new drug made by Bristol Myers Squibb and authorized by the FDA final week, triggers muscarinic receptors as an alternative of dopamine receptors. It is the primary schizophrenia therapy to take action.
Bristol Myers Squibb
cover caption
toggle caption
Bristol Myers Squibb
Cobenfy, a brand new drug made by Bristol Myers Squibb and authorized by the FDA final week, triggers muscarinic receptors as an alternative of dopamine receptors. It is the primary schizophrenia therapy to take action.
Bristol Myers Squibb
For the previous 70 years, schizophrenia therapies all focused the identical chemical: dopamine. Whereas that works for some, it causes brutal unintended effects for others.
An antipsychotic drug authorized final month by the FDA modifications that. It triggers muscarinic receptors as an alternative of dopamine receptors. The drug is the results of an opportunity scientific discovering … from a examine that wasn’t even targeted on schizophrenia.
This episode, host Emily Kwong and NPR pharmaceutical correspondent Sydney Lupkin dive into the place the drug originated, the way it works and what it would shift for folks with schizophrenia.
Learn extra of Sydney’s reporting on this new therapy.
This episode was produced by Hannah Chinn and edited by our showrunner, Rebecca Ramirez. The info have been checked by Tyler Jones. The audio engineer was Maggie Luthar.
Take heed to Brief Wave on Spotify and Apple Podcasts.
Pay attention to each episode of Brief Wave sponsor-free and assist our work at NPR by signing up for Brief Wave+ at plus.npr.org/shortwave.
This episode was produced by Hannah Chinn and edited by Rebecca Ramirez. It was fact-checked by Tyler Jones. Maggie Luthar was the audio engineer.